---
title: "Pre-market hot trades in the US stock market: Revolution Medicines down 9.00% in pre-market; Above Food Ingredients up 7.72% in pre-market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271908512.md"
description: "Revolution Medicines pre-market down 9.00%; Above Food Ingredients pre-market up 7.72%; CIMG pre-market up 34.26%; ECD Automotive Design pre-market up 31.77%; PMGC pre-market up 25.65%"
datetime: "2026-01-08T09:26:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271908512.md)
  - [en](https://longbridge.com/en/news/271908512.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271908512.md)
---

# Pre-market hot trades in the US stock market: Revolution Medicines down 9.00% in pre-market; Above Food Ingredients up 7.72% in pre-market

**Pre-market Hot Trades in US Stocks**

Revolution Medicines is down 9.00% in pre-market trading. Based on recent news,

1.  On January 8, AbbVie is in advanced negotiations to acquire the cancer-focused biotech company Revolution Medicines, with a deal value potentially exceeding $20 billion. The stock price of Revolution Medicines surged by about 30%, triggering multiple volatility trading halts, while AbbVie’s stock rose by 5%;
    
2.  On January 7, AbbVie was in deep negotiations to acquire Revolution Medicines, and if no obstacles arise in the final stages of negotiations, the deal could be reached soon. Following this news, fellow oncology treatment company Erasca saw its stock soar by 27%, before being halted due to excessive volatility;
    
3.  On January 8, after trading was paused due to volatility, Revolution Medicines' stock briefly resumed trading, rising 28.9% to $102.90. Market news indicates that AbbVie is close to finalizing the acquisition of Revolution Medicines.
    

Above Food Ingredients is up 7.72% in pre-market trading, with no significant news recently. The trading is active, with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

**Top Gainers in Pre-market US Stocks**

CIMG is up 34.26% in pre-market trading, with no significant news recently. The trading is active, with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

ECD Automotive Design is up 31.77% in pre-market trading, with no significant news recently. The trading is active, with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

PMGC is up 25.65% in pre-market trading. Based on recent key news:

1.  On January 6, PMGC Holdings announced a 1-for-4 reverse stock split, leading to a rise in stock price. This split will reduce the number of shares outstanding and adjust the stock price, with investors responding positively to the news, driving the stock price up.
    
2.  On January 6, PMGC Holdings announced a strategic acquisition of a non-controlling stake in Nuclea Energy Inc, further enhancing the company's positioning in the nuclear energy sector. This move is seen by the market as a positive signal for the company's future growth, resulting in a rise in stock price.
    
3.  On January 6, PMGC Holdings announced that it would adopt a new CUSIP number while maintaining the existing trading code. This move aims to simplify the stock trading process, enhance market confidence, and drive the stock price up. The nuclear energy sector has performed strongly recently, with clear policy support

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [ABVE.US](https://longbridge.com/en/quote/ABVE.US.md)
- [ABVEF.US](https://longbridge.com/en/quote/ABVEF.US.md)

## Related News & Research

- [Above Food Engages Counsel as It Appeals Nasdaq Delisting Over Filing Delays](https://longbridge.com/en/news/293241139.md)
- [Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?](https://longbridge.com/en/news/291733272.md)
- [European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process | RVMD Stock News](https://longbridge.com/en/news/291941503.md)
- [Revolution Medicines reports release available on zoldonrasib combination data in RAS G12D metastatic pancreatic cancer](https://longbridge.com/en/news/291543920.md)
- [Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Johnson & Johnson (JNJ)](https://longbridge.com/en/news/291688906.md)